Crystal structure of cancer-specific anti-HER2 antibody H2Mab-250 in complex with epitope peptide
2-Gaussian fit: Grosse-Kunstleve RW, Sauter NK, Adams PD: Newsletter of the IUCr Commission on Crystallographic Computing 2004, 3, 22-31.
Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy.
Metastatic lymph node gene 19 protein,MLN 19,Proto-oncogene Neu,Proto-oncogene c-ErbB-2,Tyrosine kinase-type cell surface receptor HER2,p185erbB2
GREVQLVESGGGLVQPGGSLKLSCAASGFTFSNYGMSWVRQTPDRRLELVATINNNGGGTYYPDSVKGRFTISRDNAKNT LYLQMSSLKSEDTAMYYCTSPGLLWDAWGAGTTVTVCSGSDYEFLKSWTVEDLQKRLLALDPMMEQEIEEIRQKYQSKRQ PILDAIEAK
GRDVVMTQTPLTLSVSIGQPASISCKSSQSLLDSDGRTYLNWLLQRPGQSPKRLIYLVSKLDSGAPDRFTGSGSGTDFTL KISRVEAEDLGVYYCWQGTHFPQTFGGGTKLEIKRGSDYEFLKSWTVEDLQKRLLALDPMMEQEIEEIRQKYQCKRQPIL DAIEAKGTLLG
The VH domain region (residues 1-113) of this chimeric protein is derived from Mus musculus, while the SARAH domain region (residues 114-164) is derived from Homo sapiens.
The VL domain region (residues 1-108) of this chimeric protein is derived from Mus musculus, while the SARAH domain region (residues 109-159) is derived from Homo sapiens.
Japan Society for the Promotion of Science (JSPS)
Fv-clasp, antibody, cancer-specific, HER2, IMMUNE SYSTEM